The significance of targeting Pin1 extends beyond cancer cells alone. Pancreatic tumors are notoriously resistant to treatment partly due to their complex microenvironment, which includes cancer-associated fibroblasts and macrophages that foster tumor growth and shield malignant cells. The UCR team’s cutting-edge Pin1 degraders also operate within these supporting stromal cells, attacking the disease from multiple cellular fronts and potentially circumventing longstanding barriers posed by the dense, fibrous tumor microenvironment. This dual targeting mechanism holds considerable promise for enhancing treatment efficacy in tumors that have been notoriously refractory to conventional chemotherapy and immunotherapy.

Led by Maurizio Pellecchia, a distinguished professor at UCR’s School of Medicine, the research team has partnered with City of Hope in Duarte, California—a premier cancer research institution—under a joint National Cancer Institute U54 grant. This collaborative effort has enabled the refinement of original Pin1 inhibitors into more stable and biologically effective compounds, capable of enduring in the bloodstream to reach tumor sites. Their work involved rigorous preclinical evaluations using patient-derived cancer-associated fibroblasts and macrophages, alongside sophisticated mouse models replicating pancreatic cancer with peritoneal metastases, which represent a critical clinical challenge.

Peritoneal metastases, often arising as severe complications in abdominal cancers such as pancreatic, colorectal, and gastric malignancies, typically herald dismal prognoses and limited therapeutic options. Patients diagnosed with these metastases face survival measured in mere months due to the near-total lack of effective interventions. The innovation demonstrated by the UCR and City of Hope collaboration is a potent Pin1-degrading agent that decisively suppresses these lethal metastatic growths in murine models, signaling a breakthrough that could translate into transformative clinical treatments for these otherwise intractable conditions.

Pin1 itself acts as a molecular regulator orchestrating the delicate balance between oncogenes and tumor suppressor proteins within cancer cells and the surrounding stroma. The approach to degrade Pin1 rather than simply inhibit its activity marks a paradigm shift in cancer therapy. By promoting the selective elimination of this enzyme, rather than its temporary blockade, the new compounds disrupt essential pathways critical for cancer cell survival, proliferation, and metastasis. This molecular ‘crowbar’ strategy is poised to advance a new class of anti-cancer drugs that remove harmful proteins completely, arguably a more effective mechanism than conventional small-molecule inhibitors.

Throughout their studies, the researchers observed that the Pin1 degraders exhibited robust activity not only against the tumor cells but also suppressed supportive stromal cells within the tumor microenvironment, profoundly limiting tumor progression. This indicates a broad-spectrum therapeutic potential which could encompass a variety of gastrointestinal and abdominal cancers beyond pancreatic cancer alone. Such an approach to cancer treatment—targeting both malignant and non-malignant tumor-associated cells—could revolutionize therapeutic outcomes by overcoming resistance mechanisms inherent in the tumor microenvironment.

The collaboration between UCR’s expertise in chemical biology and modern drug discovery and City of Hope’s strengths in cancer biology and clinical oncology embodies a robust model for translational science. The U54 grant from the National Cancer Institute has been pivotal in enabling this multidisciplinary integration, fostering long-term partnerships that aim to rapidly propel these promising preclinical findings from bench to bedside. The goal is clear: to develop Pin1 degraders into clinically translatable therapeutics capable of improving survival and quality of life for patients devastated by highly aggressive cancers.

Lead scientists emphasize the dire need for these therapeutic innovations, especially given the grim statistics associated with pancreatic cancer. Patients with peritoneal metastases typically survive less than three months without effective interventions. The Pin1-targeting compounds, by mitigating tumor growth and spread in animal models, offer a scientific rationale to move toward human clinical trials with hope for substantial impact. They envisage these agents complementing existing chemotherapy and immunotherapy regimens by sensitizing resistant tumor cells and their microenvironment.

Further technical elaboration reveals that the Pin1-degrading molecules developed are engineered to bind Pin1 with high affinity, inducing conformational destabilization and marking it for proteasomal degradation. This mechanochemical process contrasts with conventional inhibitors that merely occupy the active site, often resulting in transient suppression rather than elimination. The chemical optimization focused on enhancing plasma stability to maintain compound activity in systemic circulation, a critical factor for therapeutic success in treating metastatic disease.

Patient-derived models used in this study underscore the clinical relevance of the findings. By assessing inhibitor effects on fibroblasts and macrophages freshly isolated from patient biopsies, the researchers validate the compounds’ functionality in biologically relevant human cellular contexts. These personalized approaches strengthen the predictive value of the preclinical data and lay the groundwork for precision medicine strategies employing Pin1 degraders tailored to individual tumor microenvironments.

In summary, this research redefines the landscape of therapeutic targeting in pancreatic and related cancers by advancing an innovative degradative approach to a pivotal oncogenic regulator. The convergence of advanced chemical design, molecular biology insights, and collaborative clinical research has yielded a novel class of agents with profound anti-tumor efficacy demonstrated in rigorous animal models of metastatic disease. With continued development and clinical translation, these Pin1 degraders represent a beacon of hope for patients confronting deadly peritoneal metastases and other stubborn gastrointestinal malignancies.

The findings were published in the prestigious journal Molecular Therapy Oncology, marking a milestone in cancer drug discovery. The research team, including key contributors from both UCR and City of Hope, exemplifies a new wave of collaborative oncology research capable of tackling some of the most intimidating challenges in cancer treatment through innovative molecular strategies.

Subject of Research: Animals
Article Title: Pre-clinical evaluation of a potent and effective Pin1-degrading agent in pancreatic cancer
News Publication Date: 31-Oct-2025
Web References: https://news.ucr.edu/articles/2024/11/11/protein-degradation-strategy-offers-hope-cancer-therapy, https://www.cell.com/molecular-therapy-family/oncology/fulltext/S2950-3299(25)00147-X
References: Pellecchia M., et al. Pre-clinical evaluation of a potent and effective Pin1-degrading agent in pancreatic cancer. Molecular Therapy Oncology, 2025. DOI: 10.1016/j.omton.2025.201078
Image Credits: Pellecchia lab, UC Riverside
Keywords: Pin1, pancreatic cancer, protein degradation, peritoneal metastases, cancer-associated fibroblasts, tumor microenvironment, targeted therapy, molecular crowbar, gastrointestinal cancers, preclinical study, NIH U54 grant, proteasomal degradation

The human gastrointestinal tract is uniquely equipped with its own extensive nervous system, often dubbed the “second brain,” which orchestrates a myriad of physiological functions critical to digestive health. Among the constituents of this enteric nervous system, neuropeptides such as CGRP function as potent signaling molecules that modulate intercellular communication by binding to specific receptors on target cells. These interactions govern diverse biological processes, including vascular modulation, immune responses, and tissue homeostasis. The new research has uncovered that within the tumor microenvironment, CGRP is not only present in nerve fibers infiltrating the neoplastic tissue but is also aberrantly synthesized by the tumor cells themselves, suggesting an autocrine loop that fosters malignancy.

This phenomenon was elucidated by a collaborative research team from the Olivia Newton-John Cancer Research Institute (ONJCRI) and the La Trobe School of Cancer Medicine, who employed sophisticated genetic engineering techniques to dissect the molecular interplay between CGRP, RAMP1, and tumor cell dynamics. By selectively knocking out the RAMP1 receptor gene in cancer cells, the researchers observed a marked attenuation of tumor growth, affirming the receptor’s critical role in this pathway. Such findings underscore a paradigm shift in our understanding of tumorigenesis, implicating the nervous system as an active participant, rather than a passive backdrop, in cancer progression.

One of the most promising aspects of this discovery lies in the translational potential it holds. Given that pharmaceutical agents targeting CGRP and RAMP1 have already received regulatory approval and are widely prescribed for the treatment of migraine headaches, there exists a tangible opportunity to repurpose these drugs as anti-cancer therapies. This strategy could dramatically shorten the timeline for clinical application, circumventing the protracted drug development and approval processes typically associated with novel cancer treatments.

Dr. Pavitha Parathan, lead author of the landmark study published in BMJ Oncology, emphasized the significance of these findings: “The presence of CGRP within tumor nerves and the ability of the cancer cells to produce CGRP themselves highlight a previously unrecognized mechanism by which tumors can manipulate their microenvironment to sustain growth.” She further elucidated the therapeutic promise by noting that existing CGRP-inhibiting drugs might offer a readily available means to disrupt this malignant crosstalk, potentially halting cancer progression with well-tolerated pharmacological agents.

The study’s senior author, Dr. Lisa Mielke, who also serves as the Laboratory Head at ONJCRI and La Trobe School of Cancer Medicine, acknowledges the exciting frontier this research opens: “The nervous system’s involvement in cancer biology is an emerging research area, ripe with opportunities for innovative therapeutic approaches. Our future work is focused on evaluating the efficacy of existing migraine medications in combating colorectal cancer, with the aim of incorporating them into clinical trials alongside standard treatment regimens.”

The global burden of gastrointestinal cancers remains immense, accounting for approximately one-quarter of all cancer diagnoses and one-third of cancer-related deaths worldwide. These statistics translate to millions of new cases and fatalities annually, underscoring the urgent need for novel, more effective treatment strategies. The identification of a druggable nerve-tumor axis offers a beacon of hope for improving patient outcomes in these challenging malignancies.

The research, supported by prestigious bodies such as the Australian National Health and Medical Research Council and the Victorian Cancer Agency, represents a highly interdisciplinary effort that included collaborations with renowned institutions like Austin Health, Monash University, Harvard University, and the Walter and Eliza Hall Institute of Medical Research (WEHI). Funding from various foundations, including the Colorectal Cancer Alliance and Tour de Cure, facilitated this comprehensive investigation.

At a mechanistic level, the role of CGRP and RAMP1 in tumor biology may involve modulation of tumor cell proliferation, angiogenesis, and evasion of immune surveillance. CGRP is known for its vasoactive properties and ability to influence inflammatory pathways, which could contribute to creating a tumor-favorable microenvironment. By interfering with CGRP/RAMP1 signaling, it may be possible to disrupt these pathological processes and restore control over unchecked cell growth.

This discovery dovetails with an evolving recognition of the tumor microenvironment’s complexity, which extends beyond cancer cells to include stromal cells, immune components, and now, importantly, neuronal elements. The interplay between these diverse cellular constituents forms a dynamic ecosystem that cancer cells exploit for survival and dissemination. Targeting neuronal signaling pathways within this milieu represents a novel therapeutic frontier.

The existing CGRP inhibitors, such as monoclonal antibodies and small molecules authorized for migraine therapy, have an established safety profile, significantly enhancing their appeal for rapid clinical translation in oncology. Future clinical trials will be crucial to determine optimal dosing, efficacy, and potential synergistic effects when combined with conventional chemotherapies or immunotherapies.

In light of these findings, the concept of cancer management is poised to incorporate neuromodulatory strategies, heralding a new era of precision medicine wherein the neurobiology of tumors is explicitly targeted. This approach aligns with ONJCRI’s mission to develop cancer treatments that are not only effective but also kinder and more tolerable for patients, potentially minimizing side effects and improving quality of life.

The impact of this research resonates globally, offering hope for millions affected by gastrointestinal cancers—a heterogeneous group of diseases that includes some of the most aggressive and treatment-resistant tumor types. By bridging fundamental neurobiological insights with translational potential, the study sets a precedent for future explorations into the neural underpinnings of cancer and the therapeutic opportunities they present.

As the oncology community anticipates the forthcoming clinical evaluations of CGRP-targeting drugs in cancer therapy, this discovery underscores the necessity of interdisciplinary research approaches that integrate neuroscience, molecular biology, and clinical medicine. The innovative repurposing of migraine drugs to combat gastrointestinal cancers exemplifies how existing pharmacological tools can be harnessed to meet urgent unmet needs, accelerating the path from bench to bedside and ultimately saving lives.

Subject of Research: Human tissue samples

Article Title: Sensory neuropeptide CGRP and its co-receptor RAMP1 drive tumour cell growth in gastrointestinal cancers

News Publication Date: 24-Oct-2025

Web References:
DOI link to the original paper

References:

1. Established roles of neuropeptides in nervous system signaling.
2. Existing FDA-approved drugs targeting CGRP and RAMP1 for migraine therapy.
3. Global epidemiology of gastrointestinal cancers.

Keywords:
Health and medicine, Clinical medicine

Gastrointestinal cancers continue to represent a formidable health challenge worldwide, often characterized by aggressive progression and limited treatment options. Regorafenib, although FDA-approved for certain GI cancers, frequently suffers from modest efficacy and substantial side effects that hinder patient outcomes and quality of life. The exploration of aramchol—a drug originally designed to combat fatty liver disease by modulating lipid metabolism—offers a fresh perspective on how cancer cell energy pathways can be exploited therapeutically. By inhibiting stearoyl-CoA desaturase 1 (SCD1), aramchol disrupts key lipid biosynthesis processes fundamental to cancer cell survival, making it an ideal candidate for combination therapies.

In laboratory experiments utilizing human hepatoma (HuH7) and colorectal cancer cell lines, the combination of aramchol with regorafenib exhibited a significantly higher tumoricidal effect than either compound alone. This enhanced potency was reflected in decreased cell viability, increased apoptotic markers, and pronounced autophagy induction. Autophagy, a cellular recycling mechanism, is often hijacked by cancer cells for survival under stress. However, this study demonstrates that the therapeutic exploitation of autophagy can lead to enhanced tumor cell death when carefully manipulated by drug combinations.

The in vivo segment of the study employed male NRG mice implanted with HuH7 cells to mimic human liver tumor growth. Treatment with aramchol and regorafenib, administered intraperitoneally at doses of 50 mg/kg and 10 mg/kg respectively, resulted in marked suppression of tumor volume over a two-week period. Crucially, this tumor growth inhibition occurred without significant loss of body weight or other observable toxicity in the treated animals, underscoring the potential clinical viability of this regimen.

At a molecular level, the combined treatment was found to have a profound impact on cellular survival signaling networks. The researchers discovered that aramchol and regorafenib synergistically inhibited multiple kinase-driven pathways, including those regulating endoplasmic reticulum (ER) stress and macroautophagy flux. These intracellular processes are pivotal for maintaining cancer cell homeostasis under adverse conditions. By disrupting such essential survival pathways, the drug duo effectively induced cellular stress responses incompatible with tumor cell viability.

A particularly notable finding relates to the genetic background of the tumor cells. The combination therapy showed pronounced efficacy in cells harboring the ATG16L1 T300 variant—a polymorphism associated with altered autophagy dynamics and more prevalent in populations of African ancestry. This highlights the importance of considering tumor genetics in designing tailored therapeutic interventions and may inform future precision medicine approaches targeting autophagy-related genes.

The capacity of aramchol to interact with other FDA-approved multi-kinase inhibitors, such as sorafenib and lenvatinib, was also evaluated. While all combinations demonstrated antitumor synergy, regorafenib stood out with the most substantial tumoricidal effect. This suggests that while aramchol’s therapeutic utility might extend beyond a single kinase inhibitor, regorafenib remains the optimal partner for maximizing the therapeutic index in GI cancers.

Given aramchol’s established safety profile in fatty liver disease clinical trials and regorafenib’s existing approval for cancer treatment, the transition to clinical testing for this combination therapy could be accelerated. However, the authors emphasize the necessity for additional preclinical studies to refine dosing strategies, understand long-term effects, and identify biomarkers predictive of treatment response before initiating early-phase clinical trials.

This research advances the concept that interfering with metabolic pathways and cellular stress responses represents a compelling strategy to overcome limitations of current monotherapies in GI oncology. By harnessing drug combinations capable of targeting multiple vulnerabilities within tumor cells, this approach not only amplifies antitumor efficacy but also holds promise for reducing adverse side effects that plagued earlier regimens.

Ultimately, this multifaceted therapeutic avenue underscores the value of personalized medicine wherein genetic variants, such as ATG16L1 T300, guide treatment decisions. If future studies validate these findings, patients with specific genetic backgrounds could benefit from customized, combination-based interventions that improve survival outcomes and quality of life.

The study’s integration of metabolic biochemistry, pharmacology, and oncology provides a robust framework for future research initiatives aimed at repurposing existing drugs in innovative combinations. Its implications resonate beyond GI cancers, potentially influencing treatment paradigms in various malignancies where metabolic and kinase signaling pathways converge.

As the scientific community continues to unravel the complexities of tumor biology, discoveries like these illuminate promising horizons where precision-targeted, metabolism-focused cancer therapeutics may become the new standard of care.

Subject of Research:
Gastrointestinal cancers, tumor cell metabolism, cancer therapeutics, autophagy, genetic variants

Article Title:
The SCD1 inhibitor aramchol interacts with regorafenib to kill GI tumor cells in vitro and in vivo

News Publication Date:
August 19, 2025

Web References:
http://dx.doi.org/10.18632/oncotarget.28762, https://www.oncotarget.com/archive/v16/

Image Credits:
© 2025 Booth et al. Creative Commons Attribution License (CC BY 4.0)